SCHEMBL126870

SCHEMBL126870

CO[Si](CCCCCCCCCCCCCCCCN)(OC)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA3 P07451 2/20 0.42
CA4 P22748 2/20 0.42
CA6 P23280 2/20 0.42
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
LMNA P02545 2/20 0.42
TSHR P16473 2/20 0.42
BLM P54132 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.39
EPHX1 P07099 1/20 0.39
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013358 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4530728 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4446544 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4527154 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4516171 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4539375 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4538853 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4535614 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL483098 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3
SCHEMBL4539329 1.00 DNM1 (0.42) DNM1CA12CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4054757-A1 MATERIALS AND METHODS FOR MIXED MODE, ANION EXCHANGE REVERSED PHASE LIQUID CHROMATOGRAPHY Waters Technologies Corporation (US) 2022-09-14 EP disclosed
CN-114650882-A Materials and methods for mixed mode anion exchange reverse phase liquid chromatography 沃特世科技公司 2022-06-21 CN disclosed
US-20210138361-A1 MATERIALS AND METHODS FOR MIXED MODE, ANION EXCHANGE REVERSED PHASE LIQUID CHROMATOGRAPHY WATERS TECHNOLOGIES CORPORATION 2021-05-13 US disclosed
EP-2214632-B1 LIGHTENING AND/OR DYEING OF HUMAN KERATIN FIBRES BY MEANS OF A COMPOSITION COMPRISING A PARTICULAR AMINO SILICON COMPOUND OREAL (FR) 2012-03-07 EP disclosed
US-8029577-B2 Lightening and/or dyeing of human keratin fibres via a composition comprising a particular amino silicon compound and composition and device L'OREAL S.A. (FR) 2011-10-04 US disclosed
US-7909889-B2 Lightening and/or coloring human keratin fibers using at least one aminotrialkoxy silane or at least one aminotrialkenyloxy silane composition L'OREAL S.A. (FR) 2011-03-22 US disclosed
US-7905927-B2 Method for lightening and/or coloring human keratin fibers using a composition comprising an aminotrialkoxy silane or aminotrialkenyloxy silane compound and device L'OREAL, SA (FR) 2011-03-15 US disclosed
US-20100303748-A1 METHOD FOR LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING A COMPOSITION COMPRISING AN AMINOTRIALKOXY SILANE OR AMINOTRIALKENYLOXY SILANE COMPOUND AND DEVICE L'OREAL S.A. (FR) 2010-12-02 US disclosed
US-20100297049-A1 LIGHTENING AND/OR DYEING OF HUMAN KERATIN FIBRES BY MEANS OF A COMPOSITION COMPRISING A PARTICULAR AMINO SILICON COMPOUND AND COMPOSITION AND DEVICE L'OREAL S.A. (FR) 2010-11-25 US disclosed
US-20100275387-A1 LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING AT LEAST ONE AMINOTRIALKOXY SILANE OR AT LEAST ONE AMINOTRIALKENYLOXY SILANE COMPOSITION L'OREAL S.A. (FR) 2010-11-04 US disclosed
US-20090123516-A1 DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-05-14 US disclosed
WO-2007019478-A2 DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS - THERAPEUTIC SAMS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303748-A1 METHOD FOR LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING A COMPOSITION COMPRISING AN AMINOTRIALKOXY SILANE OR AMINOTRIALKENYLOXY SILANE COMPOUND AND DEVICE KRT18, FABP4, APMAP DNM1 4388/4885CA12 1685/4885CA1 2393/4885
US-20100275387-A1 LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING AT LEAST ONE AMINOTRIALKOXY SILANE OR AT LEAST ONE AMINOTRIALKENYLOXY SILANE COMPOSITION KRT18, FABP4, ALDH7A1 DNM1 4652/4885CA12 723/4885CA1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.